InsidersTradesSigma
Track the Cencora, Inc. stock price and the full management transaction log of the company, a publicly traded company based in United States. Shares are listed on the US market, under the oversight of SEC (Form 4). Operating in the Healthcare & Pharma sector, Cencora, Inc. has recorded 226 public disclosures. Market capitalisation: €2.4bn. The latest transaction was filed on 25 August 2026 (Cession). Among the most active insiders: Mauch Robert P.. The full history is openly available.
226
Insider Decl.
n/a
Thresholds
€1m
4 ops.
Buy Volume
€3bn
37 ops.
Sell Volume
Analyst consensus: bullish or bearish?
Analysts rate Cencora, Inc. Strong Buy (bullish), based on 12 analysts. Average price target: US$62.05.
31Σ signal
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Fundamental score
Ranked 27,566 of 29,053 companies
16.0
score / 100
Value19
Quality13
FCF yld-6.1%
Earn yld-7.7%
EV/EBITDA·
ROE-40%
Gross mgn3.6%
Net mgn-0.0%
Debt/EBITDA·
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI analysis generation is paused.
Last declaration on 25 August 2026
Declarations226 total
11,300.471 shares@ US$324.116Common StockSEC:0001882641-26-000008:0
11,301 shares@ US$324.10070.15% mcap43.8% of flowCommonSEC144:0001959173-26-006372
20,000 shares@ US$316.65480.27% mcap37.9% of flowCommonSEC144:0001959173-26-005708
97 shares@ US$311.340.0013% mcap11.7% of flowCommon StockSEC:0001765744-26-000008:0
97 shares@ US$311.340.0013% mcap55.9% of flowCommon StockSEC:0001555614-26-000008:0
113 shares@ US$311.340.0015% mcap9.3% of flowCommon StockSEC:0001685596-26-000006:0
58.204 shares@ US$240.5330.0006% mcap0.3% of flowCommon StockSEC:0001774724-26-000006:0
49.889 shares@ US$240.5330.0005% mcap0.3% of flowCommon StockSEC:0001882641-26-000006:0
550 sharesCommon StockSEC:0001765744-26-000006:0
Canonical exit: 20 Sept 2026 (T+90)
4,000 sharesCommon StockSEC:0001202358-26-000006:0
Canonical exit: 16 Sept 2026 (T+90)
4,000 shares@ US$266.260.046% mcap90.1% of flowCommon StockSEC:0001202358-26-000004:0
Canonical exit: 26 Aug 2026 (T+90)
12,623 shares0Common StockSEC:0001882641-26-000004:0
8,415 shares0Common StockSEC:0001774724-26-000004:0
12,623 shares0Common StockSEC:0001333281-26-000002:0
557 shares@ US$359.2847.6% of flowCommon StockSEC:0001986505-26-000002:0
84 shares@ US$359.2212.7% of flowCommon StockSEC:0001765744-26-000002:0
69 shares@ US$359.22100.0% of flowCommon StockSEC:0001555614-26-000004:0
557 shares@ US$359.28100.0% of flowCommon StockSEC:0001449522-26-000002:0
557 shares@ US$359.2814.5% of flowCommon StockSEC:0001234234-26-000002:0
557 shares@ US$359.28100.0% of flowCommon StockSEC:0001891346-26-000002:0
557 shares@ US$359.2868.5% of flowCommon StockSEC:0001763963-26-000004:0
98 shares@ US$359.229.9% of flowCommon StockSEC:0001685596-26-000002:0
557 shares@ US$359.28100.0% of flowCommon StockSEC:0001643746-26-000002:0
905 shares@ US$359.2821.5% of flowCommon StockSEC:0001202358-26-000002:0
3,762 shares@ US$86.091.9% of flowCommon StockSEC:0001633897-26-000006:0
25 of 226 declarations
About Cencora, Inc.
Cencora, Inc. (NYSE: COR) is a major healthcare infrastructure and pharmaceutical distribution company based in Conshohocken, Pennsylvania, United States. Formerly known as AmerisourceBergen, the company rebranded as Cencora to better reflect its expanding global footprint and its central role in improving access to medicines across the healthcare supply chain. For international equity investors, Cencora is best understood not as a traditional drug manufacturer, but as a critical intermediary and service platform connecting pharmaceutical manufacturers, healthcare providers, pharmacies, and specialty practices. ([investor.cencora.com](https://investor.cencora.com/news/news-details/2023/AmerisourceBergen-becomes-Cencora-in-alignment-with-the-companys-growing-global-footprint-and-central-role-in-pharmaceutical-access-and-care/default.aspx?utm_source=openai)) The company reports two principal segments: U.S. Healthcare Solutions and International Healthcare Solutions, with certain businesses grouped in Other. Its core business remains wholesale pharmaceutical distribution, but Cencora has steadily expanded into higher-value services that support the commercialization and delivery of complex therapies. These include specialty distribution, patient and provider support services, logistics integration, data and analytics, and services for physician practices and care networks. This mix gives Cencora exposure to faster-growing areas of healthcare, particularly specialty care, oncology, ophthalmology, and advanced therapies. ([investor.cencora.com](https://investor.cencora.com/news/news-details/2026/Cencora-Reports-Fiscal-2026-First-Quarter-Results/default.aspx?utm_source=openai)) In competitive terms, Cencora holds a strong scale position in U.S. pharmaceutical distribution, an industry defined by high regulatory, logistical, and technology barriers. The company emphasizes its ability to improve product access, traceability, inventory resilience, and supply-chain efficiency. At the same time, management is actively broadening the platform through targeted investments in specialty healthcare. In 2025, Cencora completed the acquisition of Retina Consultants of America (RCA), strengthening its specialty management services platform. The company also announced plans to invest about $1 billion through 2030 to expand and harden its U.S. distribution network, including added capacity and improved resilience. ([cencora.com](https://www.cencora.com/newsroom/cencora-advances-specialty-leadership-through-acquisition-of-retina-consultants-of-america?utm_source=openai)) Recent developments underline this strategy. In 2025, Cencora reported growth in revenue and adjusted earnings, supported by underlying market expansion and acquisition-driven contributions. In 2026, the company announced acceleration of its OneOncology investment and a transaction involving MWI Animal Health and Covetrus, further reinforcing its specialty and animal-health platforms. Taken together, these moves point to a company pursuing a balanced strategy: defend its scale leadership in pharmaceutical distribution while building a broader, higher-margin services ecosystem around specialty care. For long-term investors, that combination offers a defensive healthcare profile with structural growth opportunities tied to the complexity of modern care delivery. ([investor.cencora.com](https://investor.cencora.com/news/news-details/2025/Cencora-Accelerates-OneOncology-Acquisition-Extending-Solutions-Offering-for-Community-Oncology/default.aspx?utm_source=openai))
